ArticleScientific reports2025
Targeting dendritic cell-specific TNFR2 improves skin and joint inflammation in a murine model of psoriatic arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Investigating Properties of Palmitoylethanolamide in Physiology and Disease: Far Beyond an Anti-Inflammatory Shield.Diseases (Basel, Switzerland) · 2026Review
- Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications.Frontiers in immunology · 2026Review
- Drug development in psoriatic arthritis: a trialtrove-based landscape analysis (1999-2025).Frontiers in immunology · 2026Review
- Hypobaric hypoxia can lead to an increase in lung dendritic cells and promote T-cell immunosuppression, thereby preventing the excessive progression of high-altitude pulmonary edema.Frontiers in immunology · 2026Article
- TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases.International journal of molecular sciences · 2025Review
- Mast cell-neuron axis as a core mechanism in chronic pruritus of atopic dermatitis: from mechanistic insights to therapeutic targets.Frontiers in immunology · 2025Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Psoriasis (PsO) and Psoriatic arthritis (PsA) are TNF-alpha-dependent immune-mediated inflammatory diseases where dendritic cells (DC) play a critical role in disease pathogenesis. Although TNF-alpha receptor 2 (TNFR2) has been implicated in the pathology of psoriatic diseases, its specific role in DC mediated responses remains unclear. To investigate the role of TNFR2 in DC in psoriatic disease, we utilized the mannan-oligosaccharide (MOS) model of PsA on mice with either TNFR2 intact or with DC-specific TNFR2 knockout (DC-TNFR2KO). We evaluated disease severity by assessing skin scaling, joint inflammation, serum cytokine profiles, and changes in the conventional type 1 dendritic cell (cDC1) population. A significant reduction in PsA-like skin scaling and joint inflammation was observed in DC-TNFR2KO mice. In control mice, MOS stimulated a robust increase in the cDC1 population, a response that was notably suppressed in the absence of DC-TNFR2. Furthermore, serum levels of key pro-inflammatory cytokines such as interleukin-12 (IL-12), TNF-alpha, IL-23 and IL-17 A were significantly diminished in DC-TNFR2KO mice following MOS exposure. Our findings provide compelling evidence that TNFR2 signaling in DC is instrumental in promoting PsA-like inflammation. These results highlight the potential of targeting the DC-TNFR2-pathways as a novel therapeutic strategy for PsA and related immune-mediated inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.